Philips fell more than 9% after the Food and Drug Administration said it is unsatisfied with the status of the company’s recall of devices to treat sleep apnea and asked for additional testing.
Philips fell more than 9% after the Food and Drug Administration said it is unsatisfied with the status of the company’s recall of devices to treat sleep apnea and asked for additional testing.